Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/107634
Title:
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer.
Authors:
Lund, B; Ryberg, M; Petersen, P M; Anderson, Heather; Thatcher, Nick; Dombernowsky, P
Affiliation:
Department of Oncology, Rigshospitalet, Denmark.
Citation:
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. 1994, 5 (9):852-3 Ann Oncol
Journal:
Annals of Oncology
Issue Date:
Nov-1994
URI:
http://hdl.handle.net/10541/107634
PubMed ID:
7848889
Type:
Article
Language:
en
ISSN:
0923-7534
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLund, Ben
dc.contributor.authorRyberg, Men
dc.contributor.authorPetersen, P Men
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorThatcher, Nicken
dc.contributor.authorDombernowsky, Pen
dc.date.accessioned2010-07-14T14:20:41Z-
dc.date.available2010-07-14T14:20:41Z-
dc.date.issued1994-11-
dc.identifier.citationPhase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. 1994, 5 (9):852-3 Ann Oncolen
dc.identifier.issn0923-7534-
dc.identifier.pmid7848889-
dc.identifier.urihttp://hdl.handle.net/10541/107634-
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectCancer Stagingen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntimetabolites, Antineoplastic-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshDeoxycytidine-
dc.subject.meshDisease-Free Survival-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshSurvival Rate-
dc.titlePhase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Rigshospitalet, Denmark.en
dc.identifier.journalAnnals of Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.